The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer Suqin HeDonald L. SmithDavid A. Proia PRECLINICAL STUDIES Open access 01 April 2014 Pages: 577 - 586
Evaluation of two 125I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma Maryline GardetteClaire ViallardFrancoise Degoul PRECLINICAL STUDIES 02 April 2014 Pages: 587 - 597
Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells Esther Z. ChenBlake A. JacobsonRobert A. Kratzke PRECLINICAL STUDIES 09 April 2014 Pages: 598 - 603
Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation Patrick T. GroganJann N. SarkariaMark S. Cohen PRECLINICAL STUDIES 10 April 2014 Pages: 604 - 617
The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein—a well-known, yet poorly understood drug transporter Maen ZeinoMohamed E. M. SaeedThomas Efferth PRECLINICAL STUDIES 22 April 2014 Pages: 618 - 625
The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways Susi BarolloLoris BertazzaCaterina Mian PRECLINICAL STUDIES 13 May 2014 Pages: 626 - 635
An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects Kwang-Hee ShinKyoung Soo LimKyung-Sang Yu PHASE I STUDIES 28 January 2014 Pages: 636 - 643
Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors Ramón SalazarAntonio CallesEmiliano Calvo PHASE I STUDIES 19 February 2014 Pages: 644 - 652
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors Colin D. WeekesMuralidhar BeeramAmita Patnaik PHASE I STUDIES 07 March 2014 Pages: 653 - 660
Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries Hideki MaedaTatsuo Kurokawa PHASE I STUDIES 11 March 2014 Pages: 661 - 669
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors Jordi RodonIrene BrañaJohanna C Bendell PHASE I STUDIES 21 March 2014 Pages: 670 - 681
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer Johanna C. BendellHeinz-Josef LenzJordan D. Berlin PHASE I STUDIES 03 April 2014 Pages: 682 - 690
Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma Takafumi UedaShigeki KakunagaAkira Kawai PHASE I STUDIES Open access 03 April 2014 Pages: 691 - 699
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors Fatima RangwalaJohanna C. BendellHerbert I. Hurwitz PHASE I STUDIES 09 April 2014 Pages: 700 - 709
Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors Brian A. CostelloMitesh J. BoradSteven R. Alberts PHASE I STUDIES 18 April 2014 Pages: 710 - 716
Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy Mehmet Asim BilenJean-Bernard DurandAung Naing PHASE I STUDIES 26 April 2014 Pages: 717 - 722
A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma Yoshihiko OokaTetsuhiro ChibaOsamu Yokosuka PHASE II STUDIES 07 March 2014 Pages: 723 - 728
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer Anita SchwandtVivian E. von GruenigenSteven Waggoner PHASE II STUDIES 12 March 2014 Pages: 729 - 738
A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma Ana De Jesus-AcostaDaniel LaheruWells Messersmith PHASE II STUDIES 27 March 2014 Pages: 739 - 745
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer Arun A. AzadEmma K. BeardsleyKim N. Chi PHASE II STUDIES 28 March 2014 Pages: 746 - 752
Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial Sung-Bae KimChanghoon YooHyun-Cheol Chung PHASE II STUDIES 09 April 2014 Pages: 753 - 761
A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma Sadahisa OgasawaraTetsuhiro Chibaand Osamu Yokosuka PHASE II STUDIES 16 April 2014 Pages: 762 - 768
Kidney injuries related to ipilimumab Hassane IzzedineVictor GueutinPhilippe Rouvier SHORT REPORT 01 April 2014 Pages: 769 - 773
Dysphonia induced by anti-angiogenic compounds Erika SaavedraAntoine HollebecqueDana M. Hartl REVIEW 18 December 2013 Pages: 774 - 782